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Summary Plasma lipoproteins, such as low-density lipoprotein (LDL), have been proposed to enhance the
delivery of hydrophobic photosensitisers to malignant tissue since tumour cells have been shown to have
increased numbers of LDL receptors. We have investigated the role of this receptor in the cellular accumula-
tion of the photosensitiser benzoporphyrin derivative (BPD). We observed that: (1) [`4C]BPD-LDL accumula-
tion by LDL receptor-negative fibroblast cell lines was insignificant compared with normal cell lines; (2) there
was no evidence that BPD dissociated from LDL during incubation with the cells; and (3) chemical acetylation
of LDL markedly decreased the uptake of ['4C]BPD-LDL. We conclude, therefore, that virtually all of the
photosensitiser accumulated by the cells was due to specific binding and internalisation via the LDL receptor.
Subsequent in vivo studies in M-1 (methylcholanthrene-induced rhabdomyosarcoma) tumour-bearing DBA/2J
mice showed that tumour accumulation of BPD associated with native LDL was significantly (P<0.01)
enhanced over that of acetyl-LDL-associated BPD. These results indicate that the LDL receptor is responsible
for the accumulation of LDL-associated BPD both in vitro and in vivo. Thus, utilisation of this delivery system
may provide for improvements in photodynamic therapy in clinical practice.
Photodynamic therapy (PDT) has been used since 1976 to
treat a wide variety of malignant tumours (Manyak et al.,
1988; Gomer et al., 1989; Henderson et al., 1992). The
therapy consists of the systemic administration of a
photosensitiser followed by exposure of the target tissue to
light of the appropriate wavelength. Light activation of the
photosensitiser results in the production of reactive oxygen
species that subsequently act as the cytotoxic agent
(Weishaupt et al., 1976). The advantage of PDT over conven-
tional therapies is that it is relatively non-invasive and has
limited toxicity (Dougherty et al., 1990). Toxicity is
minimised by the ability to restrict the light activation to the
tumour site and increased accumulation of the photosen-
sitiser within tumour tissue compared with unaffected tissue
(Moan & Berg, 1992). Relatively little is known about the
mechanisms governing the accumulation of photosensitisers
in tumours. However, plasma lipoproteins are thought to
play a key role since they act as high-capacity carriers of
hydrophobic photosensitisers in the blood (Barel et al., 1986;
Kessel, 1986). Many malignant tissues express an increased
number of low-density lipoprotein (LDL) receptors compared
with normal tissues (Ho et al., 1979; Gal et al., 1981; Vitols
et al., 1984), suggesting that LDL should be the ideal vehicle
for delivery of anti-cancer agents, including photosensitisers
(Norata et al., 1984; Lundberg, 1991).
LDL is the class of plasma lipoprotein particles which
carries the majority of cholesterol and cholesteryl esters in
plasma (Gotto et al., 1986). Approximately half of plasma
LDL is removed by the high-affinity LDL receptors in the
liver, and the remainder gains access to extravascular com-
partments of other tissues and organs, where LDL receptors
mediate the delivery ofcholesterol to peripheral cells (Attie et
al., 1982). Thus, the distribution of LDL to extrahepatic
tissues depends upon the rate of transcapillary transport and
the number of LDL receptors on cell surfaces. Increases in
the permeability of tumour vasculature (Paterson & Apperg-
ren, 1973) and the number of LDL receptors on tumour cells
(Ho et al., 1979; Gal et al., 1981; Vitols et al., 1984) suggest
that tumours would be a major extrahepatic site of LDL
clearance. Thus, photosensitisers associated with LDL might
accumulate in tumour tissue provided that they did not
interfere with recognition of the LDL by the LDL receptor.
Our previous studies have shown that the highly cytotoxic
photosensitiser benzoporphyrin derivative (BPD) has a
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strong affinity for lipoproteins when mixed with plasma in
vitro or in vivo (Allison et al., 1990). In subsequent
experiments in tumour-bearing mice, administration of BPD
premixed with LDL resulted in enhanced delivery to tumours
and increased photosensitisation when compared with BPD
administered in aqueous solution (Allison et al., 1991).
Similar studies by other groups have demonstrated that the
association of haematoporphyrin, haematoporphyrin
derivative and Photofrin with LDL can lead to enhanced
delivery to tumours in mice (Jori et al., 1984; Candide et al.,
1986). In light of these reports and our evidence that LDL
association enhances delivery of BPD to tumour tissue, we
hypothesised that receptor-mediated endocytosis of BPD-
LDL complexes might be an important mechanism in the
selective accumulation of this photosensitiser in tumour tis-
sue. In the present study, we have determined the role of the
LDL receptor in the binding and internalisation of BPD-
LDL mixtures of fibroblasts and M-1 tumour cells in vitro. In
addition, we investigated the contribution of LDL receptor-
mediated delivery by BPD-LDL complexes to tumours in
mice. The results clearly indicate that the LDL receptor is
responsible for virtually all the accumulation of BPD-LDL
complexes in vitro and is also a major contributor to the
selective delivery of this photosensitiser to tumours in
vivo.
Materials and methods
Cell lines
Human fibroblast cell lines were purchased from the Human
Genetic Mutant Cell Repository (Coriell Institute for
Medical Research, Camden, NJ, USA). GM3348B is a nor-
mal fibroblast cell line and GM2000E is a mutant fibroblast
cell line which has no LDL receptors. The fibroblasts were
grown in Dulbecco's modified Eagle medium (DMEM,
Gibco, Grand Island, NY, USA) with 20% fetal calf serum
(FCS). The M-1 cell line is a rhabdomyosarcoma of DBA/2J
mice which has been maintained in this laboratory in vitro
and in vivo for the past decade (Richter et al., 1987). All cell
lines were maintained in a humidified 5% carbon dioxide
incubator.
Photosensitiser
BPD was produced from haematoporphyrin via protopor-
phyrin as previously described (Panka et al., 1986) and
'." Macmillan Press Ltd., 1994 Br. J. Cancer (1994), 69, 833-839834 B.A. ALLISON et al.
obtained from Quadra Logic Technologies. The structure of
BPD is shown in Figure 1. One of the structural analogues of
the previously described synthetic process, BPD-MA, was
used exclusively in these studies and will be referred to as
BPD hereafter (Richter et al., 1987). ['4C]BPD was syn-
thesised in the laboratory of D. Dolphin, in the Department
of Chemistry, University of British Columbia (Richter et al.,
1991). BPD concentration was measured by reading the
absorbance at a wavelength of 688 nm in a solution of 50%
methanol, 1% Triton X-100 in PBS. An extinction coefficient
of 23,384.6 M-l cm-' was used to calculate the concentration
of such BPD solutions.
Lipoprotein preparation
LDL was isolated from fresh human plasma by sequential
ultracentrifugation at a density of 1.019-1.063 g ml-' (Havel
et al., 1955). Following isolation, the LDL was dialysed for
24 h against two changes of a Tris-EDTA buffer
(0.15 M sodium chloride, 10 mM Tris-HCl, 0.10% EDTA,
0.05% sodium azide, pH 7.4) at 4°C. The lipoprotein concen-
tration was estimated by analysis of protein content (Lowry
et al., 1961), and the purity of each preparation was deter-
mined by agarose gel electrophoresis (Nobel, 1968). Each
LDL preparation was stored at 4°C and used within 2 weeks
of isolation.
Purified LDL was iodinated using an adaptation of the
iodine monchloride method described by McFarlane (1958).
['251]LDL was not used unless the specific activity fell in the
range 200-400 c.p.m. ng '. In the cellular accumulation
studies, a working stock of [251I]LDL was prepared by dilu-
tion with DMEM/1% lipoprotein-deficient fetal calf serum
(LPDFCS, Sigma, St Louis, MO, USA). A total of 10 ml was
prepared at a concentration of 50 c.p.m. ng1' and
0.5 mg ml-' protein.
Acetylated LDL (Ac-LDL) was prepared by reacting the
free amino groups of the lipoprotein with acetic anhydride.
This process increases the net negative charge and destroys
the ability of the lipoprotein particle to bind to the LDL
receptor (Basu et al., 1976). The increase in net negative
charge also increases the electrophoretic mobility of the
acetylated LDL; therefore, agarose gel electrophoresis
(Nobel, 1968) was used to confirm that the LDL had been
successfully acetylated. The trinitrobenzenesulphonic acid
(TNBS) assay (Habeeb, 1966) indicated that 30% of the free
amino groups in the LDL preparation had been modified.
['4C]BPD or BPD was equilibrated with LDL, ['251I]LDL or
Ac-LDL by incubation for 30 min at 37°C before addition to
the cells or use in vivo. This equilibration resulted in the
association of all of the BPD with the LDL or Ac-LDL as
shown by gel filtration chromatography (data not shown).
The concentrations of BPD, LDL and Ac-LDL used in each
preparation are reported in the individual experiments.
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Figure 1 Structure of benzoporphyrin derivative. R3 represents
the hydrolytic site for formation of the mono- and diacid
derivatives. BPD monoacid ring A (BPD-MA) was used exclus-
ively in these studies.
Accumulation of['4C]BPD-LDL or ['4C]BPD-Ac-LDL by
culturedfibroblasts in vitro
Fibroblast cells (1 x 105) were seeded into 60 mm Petri dishes
containing 3 ml of DME with 20% fetal calf serum (FCS) on
day zero. On day 3, the medium was replaced with fresh
medium containing 10% FCS. On day 5 or 6, when the cells
were approximately 80% confluent, each dish was washed
with 2 ml of PBS and the medium was replaced with 2 ml of
DME containing 2.5 mg ml-' LPDFCS. Incubation of the
cells in LPDFCS serves to increase the number of LDL
receptors per cell (Goldstein et al., 1983). The binding and
uptake of the BPD-LDL mixtures was studied after the cells
had been incubated for 48 h in medium with LPDFCS.
Prior to each experiment, the medium was removed from
the dishes and the cells were washed once with 2 ml of PBS.
The PBS was replaced with 1 ml of DME containing the
appropriate concentrations of BPD and LDL or Ac-LDL
and 1% LPDFCS in the presence or absence of 25-fold
excess LDL or Ac-LDL. The cells were incubated in these
solutions for 2 h at 37°C. The dishes of cells were then
transferred to 4°C and washed three times for 2 min with 4°C
PBS containing 2 mgml1' BSA, followed by two 2 min
incubations in 4°C PBS. The cells were then dissolved by
exposure to 1 ml of 0.1 M sodium hydroxide for 30 min. One
aliquot of the cell lysate (750 tl) was used to determine the
amount of [14C]BPD that was associated with the cells.
Another aliquot (50pl) was used to determine the amount of
cellular protein per dish using the Lowry procedure (Lowry
et al., 1961).
Comparison of['4C]BPD-LDL andBPD-['25I]LDL
accumulation by culturedfibroblasts
In these experiments, the accumulation of BPD-LDL by
normal fibroblasts was studied using both ['4C]BPD-LDL
and BPD-[251I]LDL as markers for LDL binding and inter-
nalisation. These experiments were performed as described
for the in vitro accumulation of ['4C]BPD-LDL except that in
this case the BPD was premixed with LDL at a constant
ratio of 5 ng BPD per ytg of LDL as the LDL concentration
was increased (corresponding to a 21:1 molar ratio of BPD-
LDL). Parallel experiments were performed with both
['4C]BPD-LDL mixtures and BPD-['25I]LDL mixtures and
compared. In the case of the BPD-[251I]LDL experiments, the
total cellular [251I]LDL was measured as indicated for the
['4C]BPD-LDL mixtures. In addition, the proteolytic hyd-
rolysis of the [251I]LDL was measured. LDL that is bound to
the LDL receptor is subsequently internalised and delivered
to lysosomes, where its protein and cholesteryl ester com-
ponents are hydrolysed. Hydrolysis of the 251I-labelled pro-
tein leads to secretion of labelled amino acids into the
medium, which were distinguished as trichloroacetic acid-
soluble material (Goldstein et al., 1974).
Accumulation of[14C]BPD-LDL by cultured M-J tumour cells
The experiments with the M-1 cells in vitro were performed
as described for the accumulation of ['4C]BPD-LDL in the
fibroblast cell lines. Increasing concentrations of BPD were
mixed with 10 jlml-' LDL before addition to these cells.
The non-specific binding of ['4C]BPD-LDL was measured in
the presence of a 25-fold excess of native LDL.
Accumulation of[4C]BPD-LDL and[14C]BPD-Ac-LDL by
tumour tissue in vivo
The accumulation of BPD into tumours was studied in
mature DBA/2J mice bearing the M-1 tumour. ['4C]BPD
(90ltCi mg 1) was equilibrated with native or Ac-LDL
(2 mgml-' in Tris-EDTA buffer) by incubating for 30 min at
37°C before intravenous injection into the tail veins of mice.
Each mouse received a dose of 4 mg of BPD per kg body
weight. They were allowed to eat and drink ad libitum.
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dislocation under halothane anaesthesia and samples of
blood, liver and tumour tissue were removed. Samples were
placed in 7 ml vials, minced and the wet weight or volume
was determined. The amount of BPD recovered in each tissue
was determined as previously described (Richter et al.,
1990).
Results
Accumulation of['4C]BPD-LDL by culturedfibroblasts
The kinetics of LDL binding and internalisation by the cell
lines used was confirmed by preliminary ['25I]LDL uptake
studies. The measured ['25I1LDL binding to the normal
fibroblasts (GM3348B) was similar to the LDL binding
curves published by (Goldstein et al. (1974), whereas no
specific binding of ['25I]LDL occurred with the receptor-
negative cells.
The ability of these fibroblasts to accumulate BPD-LDL
was studied at several concentrations of ['4C]BPD which had
been pre-equilibrated with 10l gml-' LDL. At this concen-
tration, non-specific binding of LDL is usually less than
5-10% of the total binding in the normal cell line (Goldstein
et al., 1983), thus differences in the uptake by the two cell
lines probably reflect differences in the activity of the LDL
receptor. Figure 2 shows the accumulation of BPD in both
cell lines. The normal fibroblast cell line displayed
concentration-dependent accumulation of ['4C]BPD-LDL,
whereas receptor-negative cells had very little ['4C]BPD
associated with them at any concentration of ['4C]BPD-LDL.
This suggested that the uptake of BPD-LDL by the normal
fibroblasts was dependent on LDL receptor-mediated
endocytosis.
Comparison of['4C]BPD-LDL and BPD-['25I]LDL
accumulation by culturedfibroblasts
In order to determine the molar ratio of the uptake of BPD
and LDL, a comparison of['4C]BPD-LDL and BPD-['251lLDL
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Figure 2 ['4C]BPD-LDL accumulation in two fibroblast cell
lines. ['4C]BPD was premixed with 10 fg ml- LDL before addi-
tion to (-) GM3348B and (x) GM2000E cell lines. Points on
the graph represent ng of BPD per fig of cell protein. Determina-
tions for each concentration of ['4C]BPD used were performed in
duplicate with each experiment being repeated three times.
Therefore, each value reported represents the average of six
determinations and the error bars represent the standard error of
these determinations.
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Figure 3 Comparison of BPD-['251I]LDL and ['4C]BPD-LDL
association with GM3348B cells. The LDL (ng tg- g cell protein)
accumulated in the fibroblasts was measured in the presence of
['4C]BPD-LDL (0) and BPD-['251]LDL (x) as a function of
increasing LDL concentration. As the LDL concentration was
increased the ratio of BPD to LDL was kept constant at 5 ng of
BPD per jig of LDL. When ['4C]BPD-LDL was used the ng of
LDL associated with the cells was calculated as a function of this
ratio in which the BPD and LDL were originally mixed. For
every ng of ['4C]BPD counted with the cells 0.2 tg of LDL was
calculated to be associated. Determinations for each concentra-
tion of LDL used were performed in triplicate and the
experiments were repeated four times. Therefore, each value
shown represents the average of 12 determinations and the error
bars represent the standard error of these determinations.
accumulation was performed on the normal fibroblasts.
Parallel dishes of cells were incubated with the two mixtures
separately for 2 h at 37C before harvesting the cells. Figure
3 shows the amount of LDL bound and internalised by these
cells as determined by the accumulation of ['4C]BPD-LDL or
BPD-[125I]LDL. The degradation of LDL was taken into
account for measurements of the accumulation of ['25I]LDL-
BPD. BPD accumulated within extrahepatic cells is thought
not to be degraded within this time frame (A.M. Richter,
1993, personal communication).
If LDL-associated BPD was endocytosed via the LDL
receptor the estimated amount of LDL taken up by the cells
would be the same regardless of which component (protein
or BPD) was labelled. Figure 3 shows that this was indeed
the case. By contrast, if BPD was transferred from the LDL
to the plasma membrane of the cells by non-specific pro-
cesses, the predicted uptake of LDL determined from the
['4C]BPD-LDL uptake study would be greater than that
measured by the uptake of BPD-['25I]LDL. Thus, the data in
Figure 3 add further support to the hypothesis that LDL-
associated BPD is delivered to cells through the LDL recep-
tor pathway. As the concentration of LDL was increased
from 10 to 50jigml-', we observed a slight increase in the
calculated association of LDL in the presence of the
['4C]BPD-LDL, however these differences were not
significant.
The effect ofLDL acetylation on ['4C]BPD-LDL
accumulation by culturedfibroblasts
Since acetylation of LDL abolishes its ability to bind to the
LDL receptor (Basu et al., 1976), we investigated the ability
of Ac-LDL to deliver BPD to normal fibroblasts. Figure 4a
shows that acetylation of LDL decreased the ability of
['4C]BPD-Ac-LDL to be bound and internalised by these836 B.A. ALLISON etal.
a on the cell. By contrast, addition of a 25-fold excess of
Ac-LDL had much less effect on the association ['4C]BPD-
en LDL with these cells, since it did not compete for the LDL
receptor.
['4C]BPD-LDL accumulation by cultured M-J tumour cells
All of the experiments with the fibroblasts described above
consistently showed that the LDL receptor was responsible
for virtually all of the accumulation of BPD-LDL observed.
To determine whether this also occurred in cell types which
would be treated by PDT, the accumulation of [14CJBPD-
LDL was also measured in M-1 tumour cells in vitro. In
Figure 5, the total accumulation of [14C]BPD-LDL observed
was proportional to the [14C]BPD concentration added to
these cells. When an excess of LDL was added to the
[14C]BPD-LDL mixture, the total accumulation of [14C]BPD-
LDL was significantly decreased. Subtraction of the amount
associated with the cells in the presence of excess LDL from
the total accumulation suggested that the majority (60-70%)
of the accumulation was LDL receptor mediated. These
20 30 40 50 results further suggest that the LDL receptor is involved in 20 30 40 50 the uptake of[14C]BPD-LDL by these tumour cells as well as
the fibroblasts.
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Figure 4 Accumulation of ['4C]BPD-LDL and ['4C]BPD-Ac-
LDL in GM3348B cells. In the same series of experiments as in
Figure 2, ['4C]BPD was premixed with 10 sgmlP LDL (0) or
Ac-LDL (A) before addition to GM3348B cells (a). In b a
25-fold excess of either LDL (A) or Ac-LDL (0) was added to
each ['4C]BPD-LDL mixture immediately prior to addition of the
solutions to the cells. (-) Ofig ml-' LDL alone. Points on the
graphs represent the ng of BPD recovered per jig of cell protein.
Determinations for each concentration of ['4C]BPD used were
performed in duplicate and the experiments were repeated three
times. Therefore, each value plotted represents the average of six
determinations and the error bars represent the standard error of
these determinations.
Accumulation of /'4C]BPD-LDL and ['4C]BPD-Ac-LDL
mixtures by tumour tissue
Since the experiments described above clearly indicated that
LDL-associated BPD was delivered to cultured cells via the
LDL receptor, we extended our studies to investigate whether
this mechanism was also involved in the delivery of LDL-
associated BPD in vivo. Therefore, the biodistribution of
BPD equilibrated with either native LDL or Ac-LDL was
compared in M-1 tumour-bearing mice. ['4C]BPD-LDL and
['4C]BPD-Ac-LDL mixtures showed several differences in
biodistribution (Table I). However, at the time that the sam-
ples were taken, the levels of ['4C]BPD-LDL and ["4C]BPD-
Ac-LDL measured in the blood were not significantly
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cells in comparison with ['4C]BPD associated with native
LDL. Since very little ['4C]BPD-Ac-LDL was accumulated by
the fibroblasts, we believe that specific binding of the
['4C]BPD-LDL mixture to the LDL receptor accounted for
virtually all of the ["4C]BPD recovered in these cells when
associated with native LDL.
In order to confirm the specificity of this process, we
studied the effect of excess LDL or Ac-LDL on ['4C]BPD-
LDL binding and internalisation by the normal fibroblasts.
Figure 4b shows that the accumulation of ['4C]BPD-LDL
was almost completely inhibited by the addition of 25-fold
excess native LDL. Presumably, inhibition was due to com-
petition with the [14C]BPD-LDL for the LDL receptor sites
BPD conc. (ng ml- ')
Figure 5 ['4C]BPD-LDL association with M-1 cells. ["4C]BPD
was premixed with lOLgml-' LDL and added to M-1 tumour
cells. The M-1 cells were grown following the method outlined
for the human fibroblasts. The association of['4C]BPD with these
cells was measured in the absence (0) and presence (-) of
25-fold excess LDL to determine the specific (x) association of
[14C]BPD-LDL with these cells. Determinations for each concent-
ration of ['4C]BPD used were performed in duplicate and the
experiments were performed three times. Therefore, each value
plotted represents the average of six determinations and the error
bars represent the standard error of these determinations.
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Table I In vivo accumulation of ['4C]BPD-LDL and ['4C]BPD-
Ac-LDL
Recovery of ['4C]BPD (ngmg-' tissue)
Tissue LDL Ac-LDL
Tumour 1.17 0.14 0.70 ± 0.08*
Liver 7.40± 1.27 3.26 ± 0.39**
Blood 1.86 ± 0.09 1.52 ± 0.28
['4C]BPD (90tLCi mg-') was equilibrated with native or Ac-LDL
(2 mgml-' in Tris-EDTA buffer) before intravenous injection into
M-1 tumour-bearing DBA/2J mice. Each mouse received a dose of
4 mg of BPD per kg body weight. At 3 h post injection mice were
sacrificed and tissue samples were excised. The ['4C]BPD (ng mg-')
recovered in each tissue was determined. The values displayed
represent the mean of samples from five mice and the standard error
of these samples. *P <0.01, **P <0.05.
different (1.9 ± 0.1 ngmg-' and 1.52 ± 0.28 ngmg-' respec-
tively, P> 0.4). Although considerable proportions of each
preparation were recovered in the liver, this was markedly
(P<0.05) higher in the presence of native LDL
(7.4 ± 1.27 ng mg-' for ['4C]BPD-LDL; 3.26 ± 0.40 ng mg-'
for ['4C]BPD-Ac-LDL). The ['4C]BPD deposited per mg of
tumour tissue in the presence of both lipoprotein prepara-
tions suggested that LDL receptor-mediated uptake of the
[14C]BPD-LDL complexes (1.17 ± 0.14) significantly
(P<0.01) enhanced the accumulation of the drug in the
tumour compared with that of the [14C]BPD-Ac-LDL com-
plexes (0.70 ± 0.08).
Discussion
In these studies, three different strategies were used to
elucidate the role of the LDL receptor in the cellular
accumulation of BPD-LDL mixtures. Fibroblast cell lines
were chosen for these studies because they have been used
extensively for characterisation of the LDL receptor (Gold-
stein et al., 1974, 1983). Marked differences were observed
between ['4C]BPD-LDL accumulation by normal and LDL
receptor-negative fibroblasts, suggesting that the LDL recep-
tor played a major role. Little difference was observed
between the accumulation of ['4C]BPD-LDL and BPD-
['251]LDL in normal fibroblasts, indicating that BPD did not
dissociate from the LDL to the cells during the incubations.
Finally, chemical acetylation of LDL allowed us to determine
directly whether the LDL receptor was involved in the
accumulation of ['4C]BPD-LDL by the cells. The difference
observed between the association of ['4C]BPD-LDL and
['4C]BPD-Ac-LDL with the normal fibroblast cell line
indicated that photosensitiser accumulation was due almost
exclusively to specific binding and internalisation via the
LDL receptor. Experiments performed using excess LDL or
acetyl-LDL confirmed these observations.
In previous in vitro studies, Candide et al. (1980) showed
that Photofrin II was taken up by cultured human fibroblasts
more efficiently when mixed with LDL than with HDL or
albumin. However, the LDL-Photofrin II uptake was greater
than expected when the cells were grown in lipoprotein-
containing medium. Under these conditions the cellular LDL
receptor expression should be low. These investigators conc-
luded that a non-specific LDL-Photofrin II uptake was
involved in addition to the LDL receptor-mediated pathway.
They later proposed that non-specific exchange ofporphyrins
between LDL and the plasma membrane occurs (Maziere et
al., 1990). In contrast, we observed very little accumulation
of ['4C]BPD-LDL by LDL receptor-negative fibroblasts. In a
separate experiment with the normal fibroblasts, equivalent
accumulation of ['4C]BPD-LDL and BPD-['251]LDL was
observed. Both these experiments suggest that the BPD did
not dissociate from the LDL and partition into the plasma
membrane of these cells. The behaviour of LDL-associated
BPD or Photofrin II may be related to the relative affinity of
these photosensitisers for the LDL. This has been reported to
be a function of the hydrophobicity of the photosensitiser
(Jori, 1989; Kongshaug et al., 1989). Thus, the nature of the
association of BPD and Photofrin II with LDL may differ,
especially since Photofrin II consists of an aggregated mix-
ture of compounds (Dougherty et al., 1987; Kessel et al.,
1987), most of which are not highly hydrophobic. Differences
in photosensitisers, such as this, may be partially responsible
for the conflicting LDL delivery results which had been
previously reported (Korbelik et al., 1990).
In vivo studies have demonstrated that the association of
several different photosensitisers with LDL can enhance their
delivery to malignant tissues (Jori et al., 1984; Zhou et al.,
1988; Maziere et al., 1991). Results of in vivo studies on the
distribution, elimination and cytotoxic effects of photosen-
sitisers in experimental tumours have been explained by
eluding to the mechanism of LDL receptor-mediated
endocytosis of photosensitisers, without experimental
confirmation of the process (Kessel, 1986; Maziere et al.,
1990; Allison et al., 1991; Richter et al., 1991). Our in vivo
studies have extended the observations of LDL receptor-
mediated accumulation of BPD in vitro to a credible
mechanism for the delivery of BPD to tumour tissue in
vivo.
We compared the ability of native LDL and acetylated
LDL to deliver BPD to M-1 tumours in vivo. Modification of
15% of the peptidyl lysines of LDL abrogates binding to the
LDL receptor (Goldstein et al., 1979; Haberland et al., 1984;
Via et al., 1992) but acetylation of >29% is necessary for
recognition of Ac-LDL by the scavenger receptor which
recognises modified LDL (Goldstein et al., 1979; Via et al.,
1992). This receptor is active on macrophage and endothelial
cells, both of which might also be involved in BPD
accumulation in the M-1 tumour. The inability of Ac-LDL
to deliver BPD to the fibroblasts in our in vitro experiments
suggests that the acetylated LDL used was no longer binding
to the LDL receptor. Normally, recognition of Ac-LDL by
the scavenger receptor leads to very rapid clearance from the
blood via the Kupffer cells of the liver (Goldstein et al., 1979;
Van Berkel et al., 1991). The markedly higher accumulation
of ['4C]BPD-LDL in the liver and the similar blood levels of
["4C]BPD-LDL and ["4C]BPD-Ac-LDL observed 3 h post
administration in vivo suggest that our Ac-LDL preparations
were not recognised by the scavenger receptor. The TNBS
assay performed on the acetylated LDL indicated that 30%
of the lysines were modified, which might not have been
sufficient for recognition by the scavenger receptor. Thus, the
difference observed in the tumour accumulation of the two
different BPD-LDL preparations was probably due exclus-
ively to LDL receptor-mediated accumulation of the native
LDL-associated BPD.
Our previous studies have suggested that the association of
BPD with LDL increases access of the photosensitiser to the
tumour cells within the tumour tissue (Allison et al., 1991).
Similarly, Zhou et al. (1988) have reported that the associa-
tion of Zn phthalocyanine with LDL increases the damage to
tumour cells (as opposed to tumour vasculature) upon
exposure to light. In the context of our present in vivo study,
it seems likely that the enhanced uptake of native LDL by
tumour cells accounts for the difference between LDL and
Ac-LDL with respect to BPD delivery to the tumour. How-
ever, our measurements of ['4C]BPD-LDL in the tumour
tissue did not distinguish between intra- and extracellular
tissue uptake. The accumulation of a portion of ['4C]BPD-
LDL and ['4C]BPD-Ac-LDL in the tumour may be extracel-
lular. Very little is currently known about the interaction of
photosensitisers with extracellular matrix components or the
effects lipoproteins may have on these interactions.
The different experimental strategies described in this
paper consistently show that the LDL receptor is responsible
for virtually all of the accumulation of LDL-associated BPD
in vitro. Extension of these studies to tumour-bearing mice
indicates that LDL receptor-mediated endocytosis also makes
a major contribution to the delivery of this photosensitiser in
vivo. Taken together, these studies suggest that LDL
receptor-mediated endocytosis contributes substantially to
the selective accumulation of BPD (and possibly other hydro-838 B.A. ALLISON et al.
phobic photosensitisers) into malignant tissues. Characterisa-
tion and utilisation of this delivery system may provide for
an improvement in PDT in clinical practice.
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